FGD3 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from Raji cells, featuring targeted disruption of the FGD3 gene. This polyclonal pool provides a loss-of-function model for studying FGD3-dependent processes, offering a versatile tool for functional genomics, signaling interrogation, and phenotypic screening in a human B-lymphocyte background without clonal selection artifacts.
Raji is a well-established human Burkitt lymphoma cell line, positive for Epstein-Barr virus (EBV). As a suspension lymphoblastoid line, Raji cells exhibit mature B lymphocyte characteristics, including surface immunoglobulin expression and antigen-presenting capacity. Their transformed phenotype and continuous growth make them a robust model for B cell biology, oncogenic signaling, and immune regulation studies, while EBV positivity adds relevance for virus?Chost interaction research.
FGD3 encodes a guanine nucleotide exchange factor (GEF) that specifically activates the small GTPase CDC42 by catalyzing GDP/GTP exchange. Signaling inputs from the B cell receptor (BCR), CD40 ligand, and IL-4 receptor, often transduced via PI3K and its product phosphatidylinositol 3-phosphate (PI3P), stimulate FGD3-GEF activity. Active CDC42 then recruits downstream effectors including PAK1 and Wiskott-Aldrich syndrome protein (WASP), which coordinate actin polymerization through the Arp2/3 complex and regulate LIMK/Cofilin-mediated filament dynamics. This cascade drives cytoskeletal reorganization, promoting filopodia formation, cell migration, and adhesion.
In Raji B cells, FGD3-mediated CDC42 activation is critical for B cell receptor signaling and immune synapse dynamics. Disruption of FGD3 impairs actin-driven processes such as migration and adhesion, which are essential for adaptive immunity. Consequently, this knockout model facilitates investigation into B cell lymphopenia, hypogammaglobulinemia, and primary immunodeficiency disorders. Moreover, as a Burkitt lymphoma line, Raji cells enable dissection of how aberrant Rho GTPase signaling contributes to lymphomagenesis and support therapeutic targeting studies.
Researchers can employ this polyclonal knockout pool in diverse functional assays. Western blotting for FGD3, CDC42, and phospho-PAK1 confirms knockout and pathway disruption; RT-qPCR quantifies FGD3 mRNA levels. Immunofluorescence staining for F-actin reveals cytoskeletal abnormalities, while Transwell migration and adhesion assays directly assess functional deficits. CDC42 activity pull-downs evaluate GEF function. These applications span B cell migration and adhesion studies, CDC42 signaling in lymphoma, immunodeficiency modeling, and Rho GTPase inhibitor screening. For further details, please contact Ascent Research.
